Oncologist: Continuation of trastuzumab combined with irinotecan after progression on prior trastuzumab therapy for HER2-positive gastric cancer does not increase survival benefit

Recently, the journal Oncologist published the results of a phase II clinical study from Japan, mainly to evaluate the progress of trastuzumab combined with standard first-line chemotherapy in patients with HER2-positive gastric cancer, followed by trastuzumab combined with irinotecan treatment.
curative effect
.

Recently, the journal Oncologist published the results of a phase II clinical study from Japan, mainly to evaluate the progress of trastuzumab combined with standard first-line chemotherapy in patients with HER2-positive gastric cancer, followed by trastuzumab combined with irinotecan treatment.
curative effect
.

Recently,

Patients enrolled in the study received trastuzumab every 3 weeks and irinotecan every 2 weeks
.

The primary endpoint was overall response rate (ORR), and secondary endpoints included subgroup analyses of progression-free survival (PFS), 6-month survival, safety, and HER2 status

Patients enrolled in the study received trastuzumab every 3 weeks and irinotecan every 2 weeks

Sixteen patients were included in the study, which was terminated early due to the small number of patients enrolled and the poor disease control rate
.

The ORR and disease control rates were 6.

Sixteen patients were included in the study, which was terminated early due to the small number of patients enrolled and the poor disease control rate

Median progression-free survival (PFS) and overall survival (OS) were 2.
4 months (95% CI, 0.
0-5.
2) and 9.
7 months (95% CI, 8.
2-11.
2), respectively
.

The 6-month PFS rate was 13.

Median progression-free survival (PFS) and overall survival (OS) were 2.

In subgroup analysis of HER2 status, median PFS was 2.
2 months (95% CI, 0.
0-5.
6) and 2.
4 months (95% CI, 0.
0-5.
0) for IHC3+ and IHC2+/FISH-positive subgroups, respectively (P =0.
993)
.

The median OS in these subgroups was 8.

In subgroup analysis of HER2 status, median PFS was 2.

The most frequently reported grade 3-4 adverse events were neutropenia (40%), anemia (27%), anorexia (33%) and fatigue (33%)
.

The most frequently reported grade 3-4 adverse events were neutropenia (40%), anemia (27%), anorexia (33%) and fatigue (33%)
.

In conclusion, after the progression of HER2-positive gastric cancer, trastuzumab combined with trastuzumab on the basis of irinotecan did not produce significant survival benefit.
Of course, the small sample size included in this study was not enough to support this conclusion
.

In conclusion, after the progression of HER2-positive gastric cancer, trastuzumab combined with trastuzumab on the basis of irinotecan did not produce significant survival benefit.
Of course, the small sample size included in this study was not enough to support this conclusion
.

After the progression of HER2-positive gastric cancer with trastuzumab, the continued combination of trastuzumab on the basis of irinotecan did not produce significant survival benefit.

Original source:

Original source:

Yasuyuki Kawamoto, Satoshi Yuki, Takashi Meguro, et al.
Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201).
The Oncologist, 2022, XX, 1–8 .
https: https://doi.
org/10.
1093/oncolo/oyab062.

Yasuyuki Kawamoto, Satoshi Yuki, Takashi Meguro, et al.
Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201).
The Oncologist, 2022, XX, 1–8 .
https: https://doi.
org/10.
1093/oncolo/oyab062.
Leave a message here